Kyverna Therapeutics Ownership | Who Owns Kyverna Therapeutics?
Kyverna Therapeutics Ownership Summary
Kyverna Therapeutics is owned by 33.40% institutional investors, 9.11% insiders, and 57.49% retail investors. Vida ventures advisors is the largest institutional shareholder, holding 10.47% of KYTX shares.
KYTX Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Kyverna Therapeutics | 33.40% | 9.11% | 57.49% |
| Sector | Healthcare Stocks | 232.51% | 10.72% | -143.22% |
| Industry | Biotech Stocks | 384.55% | 10.58% | -295.13% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Vida ventures advisors | 4.52M | 10.47% | $27.14M |
| Gilead sciences | 4.13M | 9.50% | $38.79M |
| Bain capital life sciences investors | 3.37M | 7.79% | $20.21M |
| Vanguard group | 1.78M | 4.10% | $16.74M |
| Price t rowe associates inc /md/ | 1.51M | 3.50% | $9.07M |
| Aigh capital management | 1.50M | 3.46% | $14.10M |
| Morgan stanley | 1.00M | 2.31% | $9.42M |
| Insight group | 989.05K | 2.29% | $5.93M |
| Propel bio management | 666.67K | 1.54% | $6.27M |
| Mbb public markets i | 614.48K | 1.42% | $3.69M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Vida ventures advisors | 4.52M | 92.41% | $27.14M |
| Propel bio management | 666.67K | 5.35% | $6.27M |
| Caxton | 18.77K | 4.12% | $176.47K |
| Aigh capital management | 1.50M | 3.41% | $14.10M |
| Gilead sciences | 4.13M | 2.00% | $38.79M |
| Peapod lane capital | 183.82K | 1.47% | $1.73M |
| Bain capital life sciences investors | 3.37M | 1.34% | $20.21M |
| Monashee investment management | 195.00K | 1.03% | $1.83M |
| Catalio capital management, lp | 586.91K | 0.65% | $3.52M |
| Mbb public markets i | 614.48K | 0.49% | $3.69M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Aigh capital management | 1.50M | 3.41% | 1.50M |
| Morgan stanley | 1.00M | 0.00% | 828.29K |
| Propel bio management | 666.67K | 5.35% | 666.67K |
| Vanguard group | 1.78M | 0.00% | 458.63K |
| Rfg advisory | 445.20K | 0.08% | 445.20K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Novo | - | - | -1.85M |
| Franklin resources | - | - | -677.59K |
| Integral health asset management | - | - | -350.00K |
| Price t rowe associates inc /md/ | 1.51M | 0.00% | -318.30K |
| Rock springs capital management lp | - | - | -178.96K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Aigh capital management | 1.50M | 3.41% | 1.50M | $14.10M |
| Propel bio management | 666.67K | 5.35% | 666.67K | $6.27M |
| Rfg advisory | 445.20K | 0.08% | 445.20K | $4.18M |
| Woodline partners lp | 252.21K | 0.01% | 252.21K | $1.51M |
| Monashee investment management | 195.00K | 1.03% | 195.00K | $1.83M |
Sold Out
| Holder | Change |
|---|---|
| Ifp advisors | -16.00 |
| Rothschild investment | -50.00 |
| Jones financial companies lllp | -81.00 |
| Sterling capital management | -186.00 |
| Raymond james financial | -189.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 62 | -21.52% | 14,501,210 | -36.11% | 33 | 1.21% | 39 | 21.88% | 12 | -53.85% |
| Sep 30, 2025 | 76 | 1.33% | 22,548,873 | 0.47% | 52 | 1.94% | 30 | -26.83% | 26 | 8.33% |
| Jun 30, 2025 | 79 | -10.23% | 23,198,522 | -10.03% | 53 | 1.51% | 44 | 4.76% | 24 | -4.00% |
| Mar 31, 2025 | 88 | -1.12% | 25,809,724 | -9.40% | 59 | 1.37% | 41 | -26.79% | 25 | 92.31% |
| Dec 31, 2024 | 90 | -4.26% | 28,867,980 | 2.72% | 66 | 1.58% | 57 | 11.76% | 13 | -38.10% |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Dec 18, 2025 | SEIDENBERG BETH C | - | Buy | $1000.00K |
| Dec 18, 2025 | Westlake BioPartners Opportunity Fund I, L.P. | - | Buy | $1000.00K |
| Dec 15, 2025 | Walker Karen Marie | Chief Technology Officer | Sell | $292.78K |
| Feb 12, 2024 | GILEAD SCIENCES, INC. | - | Buy | $20.02M |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | - | - |
| 2025 Q4 | 2 | 1 |
| 2025 Q2 | - | - |
| 2025 Q1 | - | - |
| 2024 Q4 | - | - |
KYTX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools